nach oben

Erschienen in:

01.05.2013

Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation

verfasst von: Michael Mok, Marina Urena, Luis Nombela-Franco, Henrique Barbosa Ribeiro, Ricardo Allende, Robert DeLarochellière, Daniel Doyle, Eric Dumont, Mélanie Côté, Josep Rodés-Cabau

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation (AF) is a common co-morbidity among patients undergoing Transcatheter Aortic Valve Implantation (TAVI). Only recently have the clinical outcomes of patients with chronic or new-onset AF after TAVI been reported. The absence of clinical trials focusing on this cohort of patients has resulted in the lack of evidence based clinical guidelines. We aim to review and discuss the current literature on AF in TAVI, its clinical implications and future perspectives.

Falk RH (2001) Atrial fibrillation. N Engl J Med 344:1067–1078PubMedCrossRef

Chugh SS, Blackshear JL, Shen WK et al (2001) Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37:371–378PubMedCrossRef

Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375PubMedCrossRef

Heeringa J, van der Kuip DA, Hofman A et al (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949–953PubMedCrossRef

Psaty BM, Manolio TA, Kuller LH et al (1997) Incidence and risk factors for atrial fibrillation in older adults. Circulation 96:2455–2461PubMedCrossRef

Cribier A, Eltchaninoff H, Bash A et al (2002) Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis. First human case description. Circulation 106:3006–3008PubMedCrossRef

Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607PubMedCrossRef

Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364:2187–2198PubMedCrossRef

Rodes-Cabau J (2012) Transcatheter aortic valve implantation: current and future approaches. Nat Rev Cardiol 9:15–29CrossRef

10.

Rodes-Cabau J, Webb JG, Cheung A et al (2010) Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 55:1080–1090PubMedCrossRef

11.

Piazza N, Grube E, Gerckens U et al (2008) Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18F) CoreValve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 4:242–249PubMedCrossRef

12.

Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308PubMedCrossRef

13.

Bosmans JM, Kefer J, de Bruyne B et al (2011) Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact Cardiovasc Thorac Surg 12:762–767PubMedCrossRef

14.

Gilard M, Eltchaninoff H, Iung B et al (2012) Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 366:1705–1715PubMedCrossRef

15.

Motloch LJ, Reda S, Rottlaender D et al (2011) Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg 93:124–131PubMedCrossRef

16.

Amat-Santos IJ, Rodes-Cabau J, Urena M et al (2012) Incidence, predictive factors and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 59:178–188PubMedCrossRef

17.

Nuis RJ, Van Mieghem NM, Schultz CJ et al (2012) Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 109:1637–1643PubMedCrossRef

18.

Linke A (2012). Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation. CoreValve ADVANCE. Paper presented at Transcatheter Valve Therapies, 2–5 June 2012

19.

Wendler O (2012). 30-day outcome from the SOURCE XT TAVI post-approval study. Paper presented at EuroPCR 2012

20.

Shahian DM, O’Brien SM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery. Ann Thorac Surg 88:S2–S22PubMedCrossRef

21.

Faxon DP, Eikelboom JW, Berger PB et al (2011) Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thromb Haemost 106:572–584PubMedCrossRef

22.

Benjamin EJ, Levy D, Vaziri SM et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271:840–844PubMedCrossRef

23.

Cox JL (1993) A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg 56:405–409PubMedCrossRef

24.

Mehta RH, Dabbous OH, Granger CB et al (2003) Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol 92:1031–1036PubMedCrossRef

25.

Al-Khatib SM, Pieper KS, Lee KL et al (2001) Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. Am J Cardiol 88:76–79CrossRef

26.

Lau DH, Huynh LT, Chew DP et al (2009) Prognostic impact of types of atrial fibrillation in acute coronary syndromes. Am J Cardiol 104:1317–1323PubMedCrossRef

27.

Kinjo K, Sato H, Sato H et al (2003) Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 92:1150–1154PubMedCrossRef

28.

Bramer S, van Straten AH, Soliman Hamad MA et al (2010) The impact of new-onset postoperative atrial fibrillation on mortality after coronary artery bypass grafting. Ann Thorac Surg 90:443–449PubMedCrossRef

29.

Mariscalco G, Klersy C, Zanobini M et al (2008) Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 118:1612–1618PubMedCrossRef

30.

Saxena A, Dinh DT, Smith JA et al (2012) Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol 109:219–225PubMedCrossRef

31.

Lehto M, Snapinn S, Dickstein K et al (2005) Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 26:350–356PubMedCrossRef

32.

Kappetein AP, Head SJ, Genereux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve replacement: the valve academic research consortium-2 consensus document. J Am Coll Cardiol 60:1438–1454PubMedCrossRef

33.

Frost L, Molgaard H, Christiansen EH et al (1992) Atrial fibrillation and flutter after coronary artery bypass surgery: epidemiology, risk factors and preventive trials. Int J Cardiol 36:253–261PubMedCrossRef

34.

Holmes DR, Mack MJ, Kaul S et al (2012) ACCF/AATS/SCAI/STS Expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 59:1200–1254PubMedCrossRef

35.

Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:2N–9NPubMedCrossRef

36.

Eltchaninoff H, Prat A, Gilard M et al (2011) Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 32:191–197PubMedCrossRef

37.

Maesen B, Nijs J, Maessen J, Allessie M, Schotten U (2012) Post-operative atrial fibrillation: a maze of mechanisms. Europace 14:159–174PubMedCrossRef

38.

O’Brien B, Pasic M, Kuppe H, Hetzer R, Habazetti H, Kukucka M (2011) A transapical or transluminal approach to aortic valve implantation does not attenuate the inflammatory response. Heart Surg Forum 14:E110–E113PubMedCrossRef

39.

Rodes-Cabau J, Webb JG, Cheung A et al (2012) Long-term outcomes following transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol 60:1864–1875PubMedCrossRef

40.

Eggebrecht H, Schmermund A, Voigtlander T, Kahlert P, Erbel R, Mehta RH (2012) Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 8:129–138PubMedCrossRef

41.

Hynes BG, Rodés-Cabau J (2012) Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art. Ann N Y Acad Sci 1254:151–163PubMedCrossRef

42.

Nombela-Franco L, Webb J, de Jaegere P et al (2012) Timing, predictive factors and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 126:3041–3053PubMedCrossRef

43.

Schroeter T, Linke A, Haensig M et al (2012) Predictors of permanent pacemaker implantation after Medtronic CoreValve bioprosthesis implantation. Europace 14:1759–1763PubMedCrossRef

44.

Neumar RW, Otto CW, Link MS et al (2010) Part 8: adult advanced cardiovascular life support. American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122(Suppl 3):S729–S767PubMedCrossRef

45.

Webb J, Rodes-Cabau J, Fremes S et al (2012) Transcatheter aortic valve implantation: a Canadian cardiovascular society position statement. Can J Cardiol 28:520–528PubMedCrossRef

46.

Ussia GP, Scarabelli M, Mule M et al (2011) Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 108:1772–1776PubMedCrossRef

47.

Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151PubMedCrossRef

48.

Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891PubMedCrossRef

49.

Lip GY (2011) Implications of the CHA(2)DS(2)-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation. Am J Med 124:111–114PubMedCrossRef

50.

Zeymer U, Zahn R, Gerckens U et al (2011) Antithrombotic therapy after transfemoral aortic valve implantation (TAVI). Potential hazard of triple-therapy. Eur Heart J 32(Abstract suppl):900

Titel: Clinical and prognostic implications of existing and new-onset atrial fibrillation in patients undergoing transcatheter aortic valve implantation
verfasst von: Michael Mok
Marina Urena
Luis Nombela-Franco
Henrique Barbosa Ribeiro
Ricardo Allende
Robert DeLarochellière
Daniel Doyle
Eric Dumont
Mélanie Côté
Josep Rodés-Cabau
Publikationsdatum: 01.05.2013
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2013
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-012-0859-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Transfemoral aortic valve implantation: bleeding events, related costs and outcomes

Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation

Incidence, predictors, origin and prevention of early and late neurological events after transcatheter aortic valve implantation (TAVI): a comprehensive review of current data

Access site bleeding after transcatheter aortic valve implantation

TAVI 2012: state of the art